Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb 1;17(2):77-90.
doi: 10.1111/j.1365-2893.2009.01246.x. Epub 2009 Dec 18.

HCV drug discovery aimed at viral eradication

R F Schinazi  1 , L Bassit, C Gavegnano
Affiliations
Review

HCV drug discovery aimed at viral eradication

R F Schinazi et al. J Viral Hepat. .

Abstract

Hepatitis C virus (HCV) causes significant morbidity and mortality worldwide with nearly 3% of the world population infected by this virus. Fortunately, this virus does not establish latency, and hence it may be possible to eradicate it. HCV is strongly associated with liver cirrhosis and hepatocellular carcinoma and is currently treated with pegylated interferon-alpha (peg-IFN-alpha) and ribavirin. Unfortunately, these limited treatment options often produce significant side effects, and currently, complete eradication of virus with combined drug modalities has not yet been achieved for the majority of chronically HCV-infected individuals. Restricted treatment options, lack of a universal cure for HCV and the link between chronic infection, liver cirrhosis and hepatocellular carcinoma necessitate design of novel drugs and treatment options. Understanding the relationship between the immune response, viral clearance and inhibition of viral replication with pharmacology-based design can ultimately allow for complete eradication of HCV. This review focuses upon significant novel preclinical and clinical specifically targeted antiviral therapy (STAT-C) drugs under development, highlights their mechanism of action, and discusses their impact on systemic viral loads and permanent clearance of infection.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Anti-HCV therapies under clinical investigation arranged by phase of clinical investigation.
Fig. 2
Fig. 2
(a) Mechanism of action for HCV entry inhibitors. Potential sites for targeted inhibition include receptors implicated in HCV entry including CD81, Claudin 1 [CLDN1], Glycosaminoglycan [GAG], Scavenger receptor type B1 [SRB1], and Low density lipoprotein receptor [LDLR]. (b) Mechanism of immunomodulators for treatment of HCV infection. Toll-like receptor [TLR] mediated production of proinflammatory cytokines TNF-α, IL-12 and IFN-α results in enhanced adaptive and innate immunity hallmarked by increased antibody production, cytotoxic function and increase phagocytic activity (1, 2, 11–12, 1522, 77, 79, 107).
See this image and copyright information in PMC

References

    1. Heathcote J, Main J. Treatment of hepatitis C. J Viral Hepat. 2005;12(3):223–235. - PubMed
    1. Kim AI, Saab S. Treatment of hepatitis C. Am J Med. 2005;118(8):808–815. - PubMed
    1. Zaman A, Fennerty MB, Keeffe EB. Systematic review: peg-interferon vs. standard interferon in the treatment of chronic hepatitis C. Aliment Pharmacol Ther. 2003;18(7):661–670. - PubMed
    1. Schinazi RF, Sommadossi JP, Thomas H. Therapies for Viral Hepatitis. London: International Medical Press; 1998.
    1. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993;74(Pt 11):2391–2399. - PubMed

Publication types

MeSH terms

Substances